Avidity Partners 13F holdings, Q1 2022
Holdings as of March 31, 2022 · filings on SEC EDGAR · latest filing →
Avidity Partners disclosed 91 US equity positions worth $4.5bn in its Q1 2022 13F filing. The largest position was AZN at 5.4% of the reported book, followed by ABBV and ARVN. Against the Q4 2021 filing, it opened 14 new positions, added to 26 and reduced 8 among the top 50 holdings.
What did Avidity Partners own in Q1 2022? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2021 |
|---|---|---|---|---|---|---|---|
| 1 | AZN ASTRAZENECA PLC | Healthcare | 5.4% | $245.5m | 3,700,000 | 29% | added |
| 2 | ABBV ABBVIE INC | Healthcare | 5.3% | $237.7m | 1,466,100 | -26% | reduced |
| 3 | ARVN ARVINAS INC | Healthcare | 4.4% | $196.2m | 2,915,300 | 15% | added |
| 4 | ELV ANTHEM INC | Healthcare | 4.4% | $196.2m | 399,400 | 24% | added |
| 5 | MRK MERCK & CO INC | Healthcare | 4.3% | $194.5m | 2,370,000 | – | new |
| 6 | AVTR AVANTOR INC | Healthcare | 4.3% | $191.7m | 5,668,300 | 18% | added |
| 7 | BAX BAXTER INTL INC | Healthcare | 3.3% | $148.5m | 1,915,500 | 9% | added |
| 8 | ZNTL ZENTALIS PHARMACEUTICALS INC | Healthcare | 3.3% | $146.6m | 3,176,999 | 17% | added |
| 9 | BIOHAVEN PHARMACTL HLDG CO L | 3.2% | $146.0m | 1,231,000 | 8% | added | |
| 10 | VRTX VERTEX PHARMACEUTICALS | Healthcare | 3.2% | $142.4m | 545,600 | 95% | added |
| 11 | UNH UNITEDHEALTH GROUP INC | Healthcare | 2.9% | $132.4m | 259,600 | 111% | added |
| 12 | UTHR UNITED THERAPEUTICS CORP DEL | Healthcare | 2.9% | $129.0m | 718,946 | 34% | added |
| 13 | HORIZON THERAPEUTICS PUB L | 2.6% | $119.0m | 1,131,400 | 12% | added | |
| 14 | MIRATI THERAPEUTICS INC | 2.5% | $114.5m | 1,393,000 | 73% | added | |
| 15 | IVERIC BIO INC | 2.4% | $109.0m | 6,475,400 | -7% | reduced | |
| 16 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 2.4% | $108.8m | 1,160,000 | -8% | reduced |
| 17 | IOVA IOVANCE BIOTHERAPEUTICS INC | Healthcare | 2.2% | $100.6m | 6,043,219 | 60% | added |
| 18 | ISRG INTUITIVE SURGICAL INC | Healthcare | 2.2% | $98.0m | 325,000 | – | new |
| 19 | CATALENT INC | 1.9% | $86.7m | 782,000 | 13% | added | |
| 20 | HUM HUMANA INC | Healthcare | 1.9% | $86.6m | 198,900 | – | new |
| 21 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 1.9% | $83.8m | 4,823,400 | 0% | held |
| 22 | BIIB BIOGEN INC | Healthcare | 1.7% | $76.9m | 365,000 | – | new |
| 23 | RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 1.4% | $63.1m | 869,000 | 24% | added |
| 24 | JNJ JOHNSON & JOHNSON | Healthcare | 1.4% | $62.7m | 354,000 | – | new |
| 25 | ACET ADICET BIO INC | Healthcare | 1.4% | $62.3m | 3,120,000 | 3% | added |
| 26 | KEZAR LIFE SCIENCES INC | 1.3% | $58.5m | 3,518,000 | 9% | added | |
| 27 | MCK MCKESSON CORP | Healthcare | 1.3% | $58.0m | 189,500 | – | new |
| 28 | ARGX ARGENX SE | Healthcare | 1.2% | $55.5m | 176,000 | – | new |
| 29 | BSX BOSTON SCIENTIFIC CORP | Healthcare | 1.2% | $53.0m | 1,196,100 | – | new |
| 30 | NTRA NATERA INC | Healthcare | 1.2% | $52.9m | 1,300,000 | 38% | added |
| 31 | EW EDWARDS LIFESCIENCES CORP | Healthcare | 1.1% | $51.8m | 440,000 | – | new |
| 32 | ARWR ARROWHEAD PHARMACEUTICALS IN | Healthcare | 1.0% | $43.9m | 955,000 | 9% | added |
| 33 | IMCR IMMUNOCORE HLDGS PLC | Healthcare | 0.9% | $40.8m | 1,363,800 | 11% | added |
| 34 | LEGN LEGEND BIOTECH CORP | Healthcare | 0.9% | $39.8m | 1,095,000 | 54% | added |
| 35 | XBI SPDR SER TR | 0.9% | $39.5m | 440,000 | – | new | |
| 36 | BHC BAUSCH HEALTH COS INC | Healthcare | 0.9% | $38.7m | 1,694,700 | – | new |
| 37 | AVIDITY BIOSCIENCES INC | 0.8% | $37.8m | 2,045,000 | 13% | added | |
| 38 | INSM INSMED INC | Healthcare | 0.7% | $31.8m | 1,354,539 | -7% | reduced |
| 39 | ATEC ALPHATEC HLDGS INC | Healthcare | 0.7% | $31.5m | 2,735,600 | -1% | reduced |
| 40 | IDYA IDEAYA BIOSCIENCES INC | Healthcare | 0.7% | $30.1m | 2,690,000 | 5% | added |
| 41 | CHEMOCENTRYX INC | 0.7% | $29.5m | 1,175,000 | 82% | added | |
| 42 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 0.7% | $29.4m | 711,000 | -8% | reduced |
| 43 | RCUS ARCUS BIOSCIENCES INC | Healthcare | 0.6% | $28.8m | 912,000 | – | new |
| 44 | NTLA INTELLIA THERAPEUTICS INC | Healthcare | 0.6% | $28.3m | 390,075 | – | new |
| 45 | PHAT PHATHOM PHARMACEUTICALS INC | 0.6% | $26.5m | 1,946,000 | 3% | added | |
| 46 | CRBU CARIBOU BIOSCIENCES INC | Healthcare | 0.6% | $25.9m | 2,819,067 | 5% | added |
| 47 | NUVB NUVATION BIO INC | Healthcare | 0.6% | $25.5m | 4,855,006 | -34% | reduced |
| 48 | BELLUS HEALTH INC NEW | 0.6% | $25.4m | 3,685,000 | -2% | reduced | |
| 49 | SEASPINE HLDGS CORP | 0.5% | $24.4m | 2,010,000 | 0% | held | |
| 50 | PEN PENUMBRA INC | Healthcare | 0.5% | $23.1m | 104,000 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.